Immunic, Inc.
IMUX
$1.19
-$0.02-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -28.81% | 4.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.26% | -4.02% | |||
| Operating Income | 10.26% | 4.02% | |||
| Income Before Tax | 24.55% | 4.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 24.55% | 4.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.55% | 4.63% | |||
| EBIT | 10.26% | 4.02% | |||
| EBITDA | 10.28% | 4.02% | |||
| EPS Basic | 24.72% | 51.49% | |||
| Normalized Basic EPS | 31.39% | 51.44% | |||
| EPS Diluted | 24.72% | 51.49% | |||
| Normalized Diluted EPS | 31.39% | 51.44% | |||
| Average Basic Shares Outstanding | 0.22% | 96.55% | |||
| Average Diluted Shares Outstanding | 0.22% | 96.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||